- Home
- GEVO vs PBYI Comparison
GEVO vs PBYI Comparison
Compare GEVO & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEVO
- PBYI
- Stock Information
- Founded
- GEVO 2005
- PBYI 2010
- Country
- GEVO United States
- PBYI United States
- Employees
- GEVO N/A
- PBYI N/A
- Industry
- GEVO Major Chemicals
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- GEVO Industrials
- PBYI Health Care
- Exchange
- GEVO Nasdaq
- PBYI Nasdaq
- Market Cap
- GEVO 402.3M
- PBYI 126.5M
- IPO Year
- GEVO 2011
- PBYI N/A
- Fundamental
- Price
- GEVO $2.65
- PBYI $2.83
- Analyst Decision
- GEVO Strong Buy
- PBYI Strong Buy
- Analyst Count
- GEVO 3
- PBYI 1
- Target Price
- GEVO $5.68
- PBYI $7.00
- AVG Volume (30 Days)
- GEVO 8.5M
- PBYI 257.4K
- Earning Date
- GEVO 11-06-2024
- PBYI 10-31-2024
- Dividend Yield
- GEVO N/A
- PBYI N/A
- EPS Growth
- GEVO N/A
- PBYI N/A
- EPS
- GEVO N/A
- PBYI 0.18
- Revenue
- GEVO $18,152,000.00
- PBYI $219,143,000.00
- Revenue This Year
- GEVO $12.11
- PBYI N/A
- Revenue Next Year
- GEVO $70.47
- PBYI N/A
- P/E Ratio
- GEVO N/A
- PBYI $15.55
- Revenue Growth
- GEVO 98.34
- PBYI N/A
- 52 Week Low
- GEVO $0.48
- PBYI $2.13
- 52 Week High
- GEVO $3.10
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- GEVO 80.99
- PBYI 59.52
- Support Level
- GEVO $1.92
- PBYI $2.79
- Resistance Level
- GEVO $1.92
- PBYI $2.93
- Average True Range (ATR)
- GEVO 0.23
- PBYI 0.12
- MACD
- GEVO 0.06
- PBYI 0.04
- Stochastic Oscillator
- GEVO 72.56
- PBYI 80.77
About GEVO Gevo Inc.
Gevo Inc is a renewable chemicals and biofuels company engaged in the development and commercialization of alternatives to petroleum-based products based on isobutanol produced from renewable feedstocks. Its operating segments are the Gevo segment, Renewable Natural Gas Segment, and the Agri-Energy segment. By its segments, it is involved in research and development activities related to the future production of SAF, commercial opportunities for other renewable hydrocarbon products and isobutanol, including the development of its biocatalysts, and the produces-pipeline quality methane gas captured from dairy cow manure.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.